Abstract Background: Melanoma is considered as one of the most aggressive and deadliest resistance. Discovery of novel multikinase inhibitors as anti-melanoma drug candidates is still needed. Methods: In this investigation, we assessed the in vitro and in vivo anti-melanoma activities of SC-535, which is a novel small molecule multikinase inhibitor discovered by us recently. We analyzed inhibitory effects of SC-535 on various melanoma cell lines and human umbilical vascular endothelial cells (HUVEC) in vitro. Tumor xenografts in athymic mice were used to examine the in vivo activity of SC-535. Results: in vitro and in vivo and considerable anti-proliferative ability against several melanoma cell lines. Oral administration of SC-535 resulted in dose-dependent suppression of tumor growth in WM2664 and C32 xenograft mouse models. Studies of mechanisms of action indicated that SC-535 suppressed the tumor angiogenesis and induced G2/M phase cell cycle arrest in human melanoma cells. SC-535 possesses favorable pharmacokinetic properties. Conclusion: All of these results support SC-535 as a potential candidate for clinical studies in patients with melanoma.
Introduction
Melanoma, a malignant tumor of skin cancer, is often considered as one of the most aggressive and deadliest cancers. The incidence rate of melanoma was reported to keep increasing over the past decades [1] . The grim situation incited a mass of investigations that focused on understanding of pathogenesis of melanoma and discovery of drugs targeting melanoma [2, 3] . Although the pathogenesis of melanoma is far from being fully understood, it has been commonly accepted that the mitogen-activated protein kinase (MAPK) signaling pathway is greatly involved in the development of melanoma [4] . Sustaining activation of MAPK is one of the typical characteristics of melanomas, and mutations of RAF, which is one of the key components of MAPK signaling pathway, are a major villain [5] . The RAF family of proteins includes three isoforms: ARAF, BRAF, and CRAF. While each isoform plays a role in the MAPK pathway, BRAF is one of the most important activators of MAPK signaling [6, 7] . Activating mutations in BRAF have been found in approximate 50% of melanomas [1] , and the most frequent BRAF mutation is the substitution of Val 600 residue by Glu (V600E) that leads to constitutive activation of BRAF independent of Ras activity [8] . Therefore BRAF has currently been thought as one of the most important therapeutic targets for the treatment of melanomas [6, 9] .
Meanwhile, similar to other solid tumors, melanomas are highly vascular tumors that frequently overexpress angiogenic factors [10, 11] . VEGF is one of the main fundamental regulating factors of tumor angiogenesis and its expression is an independent predictive factor of overall survival (OS) in melanomas [12, 13] . These suggest the plausibility of targeting VEGF mediated tumor angiogenesis clinically [14] . Nevertheless, such antiangiogenic strategies are less well studied in melanomas compared with some other solid tumor types. Although exact reasons responsible for this situation are unknown, the unimpressive clinical [15] [16] [17] . However, VEGF signaling remains an attractive drug target and new inhibitors such melanomas [18, 19] .
It is reasonable to hypothesize that multi-targeted agents that can simultaneously sup- WT , and CRAF are key components of the MAPK signaling pathway. SC-535 showed considerable potency against melanoma both in vitro and in vivo. In this account, we report the assessment of anti-melanoma activities of SC-535 in vitro and in vivo, as well as its mechanisms of action.
Kinase inhibition assays
vice (Millipore, Billerica, MA USA).
Cell growth inhibition assays
Anti-proliferative activities of compounds were measured using 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assays and EdU incorporation assays as previously described [24] . Various cells (2~8×10 3 cells/well) were treated with indicated concentrations of SC-535 for 72 h. Each assay was performed in 3 replicates. The IC 50 values were calculated by GraphPad Prism 5.01 software (Prism Statistical Software). EdU is a thymidine analogue used for marking the proliferating cells, which can insert into replicating DNA during S phase [25] . HUVEC growing in 96-well plates (1×10 4 cells/well) were treated with SC-535 for 24 h. Then, the proliferative cells were assayed with an EdU-Apollo ® 567 (RiboBio, Guangzhou, China) DNA Proliferation Detection kit according to the manufacturer's instructions. Images were taken by High Content Screening and Analysis (Thermo Fisher Cellomics).
FCM assays were carried out as described previously [26] . FCM assays were adopted to examine the cell cycle status with and without SC-535 treated. Cell culture and drug treatment with different concentrations were done as described above. Cells were collected and washed with cold PBS. Then 0.4 ml hypotonic X-100 was added to cells and 40000 cells were analyzed by FCM (ESP Elite, Beckman-Coulter, Miami, FL, USA).
Wound healing assay
Monolayer HUVEC were wounded by scratching with pipette tips and washed with EBM-2 medium (without growth factors). Fresh EGM-2 medium (containing various growth factors) containing vehicle or -cence microscope (Carl Zeiss Microimaging Inc.) after 24 h.
Transwell invasion assay
Invasion assays were carried out as described previously [27 -4 HUVEC. The top chamber contained vehicle or various concentrations of SC-535. Cells were allowed to migrate for 24 h. Nonmigrated 
Western blot analysis
In assays for determining the inhibitory effects of SC-535 on VEGFR2-dependent signaling cascade, HUVEC were serum starved overnight, and then incubated with SC-535 for 2 h and stimulated by VEGF (50 ng/ml) for 10 min. Cells were lysed with ripa buffer (Biotime) containing 0.1% PMSF and 1% proteinase inhibitor cocktail (Sigma, Saint Louis, MO, USA). Protein concentrations were determined using Bio-read Protein Assay Kit (Bio-Rad, USA) and equalized before loading. Forty micrograms of cellular protein from -nology, USA; Abcam Biocamicals, UK). In assays for examining the mechanisms of action of SC-535 on the melanoma cells, WM2664 cells were incubated with SC-535 for 24 h. Expression levels or activation status of MAPK signaling proteins, apoptosis associated proteins, and cell cycle related proteins were detected in WM2664 melanoma cells.
in vivo antiangiogenic activity. 30 embryos per experimental group were used in our study, and each experiment was performed in 3 replicates. Embryos placed in 24-well plates were maintained in Holtfreter's solution in a -ped with an AxioCam MRc5 digital CCD camera (Carl Zeiss Microimaging Inc.)
An alginate-encapsulate assay was performed as described [29 5×10 4 tumor cells per bead were formed and implanted s.c. into both dorsal sides of the athymic mice. Then mice were orally gavaged with SC-535 at 40 mg/kg, 20 mg/kg or vehicle once a day for 14 day (d). At the end of experiment, 0.1 ml of 2% FITC-dextran solution (Sigma, Saint Louis, MO, USA) was injected i.v. into the lateral tail vein of mice. After being exposed surgically, alginate beads were removed and photographed within 20 min. And the uptake of FITC-dextran was detected as described previously [29] .
Animal studies were conducted in conformity with institutional guide for the care and use of laboratory animals. All mouse protocols were approved by the Animal Care and Use Committee of Sichuan University (Chengdu, Sichuan, China). Six-week-old female athymic (nu/nu) mice were obtained from Chinese Academy of Medical Science (Beijing, China). WM2664 and C32 tumors were established by s.c. injection of 1×10 7 cells, respectively. After about two weeks, mice bearing tumors around 150-200 mm 3 were selected and randomized into treatment groups (6 mice per group). The animals were orally gavaged daily with SC-535, sorafenib and vehicle control. Tumor length and width were measured every three days, and tumor volume (TV) was calculated using the following expression: TV = length×width 
Cellular Physiology and Biochemistry
To investigate whether SC-535 inhibited tumor growth by suppressing tumor angiogenesis, we examined the vessel density in tumor tissue as described previously [30] . Frozen sections of WM2664 and C32 tumor xenografts were used to determine vessel density with an anti-CD31 antibody (BD Biosciences, Franklin Lakes, NJ, USA).
Blood from Sprague-Dawley rats with i.v. or p.o. 10 mg/kg SC-535 was collected in heparin-containing tubes and the plasma was isolated by the centrifugation. Plasma concentrations of SC-535 were determined by liquid chromatography/mass spectrometry (LC/MS).
Statistical analysis
The data are reported as the mean ± SEM. Student's t-test was used to analyze differences (Prism Sta-P < 0.05.
Results
kinases is shown in against other selected 28 protein kinases. These data demonstrate that SC-535 is a multikinase inhibitor that potently inhibits VEGFR1/2/3, B-RAF, and C-RAF.
The cell growth inhibitory potencies of SC-535 against various melanoma cell lines, including those bearing BRAF WT and mutated BRAF, were examined, and the results are pre- To assess the antiangiogenic effects of SC-535, the antiproliferative ability of SC-535 method. SC-535 showed a good antiproliferative activity against VEGF-stimulated HUVEC with an IC 50 of SC-535 (Table 3) . These results indicate that SC-535 exerts its antiangiogenic function ththe number of proliferating cells (red nuclei) compared with the control in EdU incorporation assays ( Fig. 2A and Fig. 2C ). Then the inhibitory effects of SC-535 to HUVEC migration, invasion, and tube formation, which are indispensable for angiogenesis, were examined. In in a dose-dependent manner and the migration ability of HUVEC was inhibited by about invasion activities of HUVEC (Fig. 2B , middle panels, and Fig. 2C ). Furthermore, we investiformation of HUVEC (Fig. 2B , down panels, and Fig. 2C ). Taken together, these data indicate that SC-535 can inhibit angiogenesis in vitro.
bit VEGFR2 and its downstream signaling in HUVEC. The results are shown in Fig. 3 . From -FR2. Consistent with the suppression of VEGFR2 activation, its downstream kinases inclu- 
In vivo antiangiogenic effects of SC-535
SC-535 in vivo -SC-535, the formation of intersegmental vessels was considerably inhibited compared with the vehicle control group, indicating a dose-dependent inhibition pattern. 
Cellular Physiology and Biochemistry
Finally, to better mimic the process of angiogenesis induced by tumor cells in vivo and determine the inhibitory effect of SC-535 on it, we performed an alginate-encapsulate tumor cell assay. In SC-535-treated mice, new blood vessels in alginate beads were apparently group (Fig. 4B) . 
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
To determine whether the killing effects of SC-535 on melanoma cell lines were due to apoptosis or cell cycle arrest, the melanoma WM2664, A2058 and CHL-1 cells were expoled a considerable increase of the number of cells in G2 phase (from 9.09% to 25.70%) with were found, which indicated that SC-535 treatment did not induce apoptosis but G2/M arrest in WM2664 (Fig. 5, up panels) . The similar effects of SC-535 on A2058 and CHL-1 were observed (Fig. 5, down and middle panels, respectively) .
To further understand the mechanisms of action, we measured the expression levels or activation status of a number of key proteins involved in the G2/M phase transition or apoptosis before and after SC-535 treated by western blot analysis in WM2664 cell line. Notably, SC-535 down-regulated CDK1 and P-Cdc25C in a dose dependent pattern (Fig. 6) ; CDK1 and Cdc25C are considered as direct regulators of G2/M phase transition. SC-535 also suppressed the activation of BRAF, CRAF, MEK, and ERK, which are important modulators of
The in vivo anti-melanoma activity of SC-535 was assessed using the WM2664 and C32 xenograft mouse models. For the WM2664 model, when the tumor grew to a volume of approximate 200 mm 3 , the mice were grouped and treated orally once daily with 12.5 mg/kg/d, 25 mg/kg/d, or 50 mg/kg/d SC-535 for about 3 weeks. The tumor volumes were measured every 3 d. It was found that 12.5 mg/kg SC-535 could suppress tumor growth with comparable to that of 50 mg/kg sorafenib. SC-535 treatment at 50 mg/kg/d showed considerable tumor suppression ability with a tumor inhibition rate of about 90% compared with loss or any other obvious signs of toxicity were observed for all of the SC-535-treated mice (Fig. 7B) .
To understand the mechanisms of action responsible for the anti-tumor effects, SC-535 was evaluated for its effects on the tumor mitotic index (Ki67) and antiangiogenesis using histological and immunohistochemical techniques. Similar to the tumor xenograft models, a dose of 50 mg/kg/d of SC-535 was administered through oral gavage for the WM2664 model. After treatment for 10 d, tumors were collected and analyzed. Tumor tissues from the vehicle group stained strongly with Ki67, indicating a large number of highly proliferative cells (Fig. 7E and Fig. 7F) . Conversely, the tumor tissues from the SC-535-treated groups showed a considerable fewer Ki67-positive cells. Immunohistochemical staining of the tumor density compared with vehicle groups (Fig. 7E and Fig. 7F ).
In the C32 xenograft model, a series of doses including 10 mg/kg, 20 mg/kg and 40 mg/kg of SC-535 were administered orally once daily when the tumors grew to 150~200 mm 3 . The tumor inhibition rates of SC-535 at doses of 10 mg/kg/d, 20 mg/kg/d, and 40 mg/kg/d are 58%, 78%, and 92%, respectively, whereas sorafenib displayed a weak tumor suppressive effect at a dose of 50 mg/kg/d (Fig. 7C) . Besides, during the whole experiment, SC-535-treated mice (Fig. 7D) .
Histological and immunohistochemical analyses were performed to examine the anti-tumor mechanisms of action of SC-535 in the C32 model. A dose of 40 mg/kg/d of SC-535 was administered orally once daily. Similar to the process for the WM2664 model, after 10 d of treatment, tumors were collected and analyzed. The percentage of Ki67-expressing cells in viable tumor tissue was considerably lower following SC-535 treatment (Fig. 7G and Fig.  7H ), indicating a considerable reduction in the number of proliferating cells in the tumors.
Furthermore, immunohistochemical analyses showed that SC-535 decreased the microvessel density compared with vehicle-treated tumors.
Pharmacokinetic parameters of SC-535 following intravenous and per os administration to male rats were measured, the results of which are summarized in Table 4 . The plasma at the dose of 10 mg/kg, SC-535 displayed a clearance of 0.022 l/h/kg, with a T 1/2 of 8.65 h. Following oral administration at a single dose of 10 mg/kg, the absorption of SC-535 was relatively quick, which reached the maximum concentration in the plasma (C max , 15.12 mg/ml) at 2 to 8 h. SC-535 displayed a clearance of 0.03 l/h/kg, with a T 1/2 of 12.61 h. The absolute oral bioavailability of SC-535 was 66.67% after an oral dose of 10 mg/kg.
Discussion
Although advanced melanoma remains an untreatable disease, considerable progress has recently been achieved in identifying the contributing oncogenes and targeted small-molecule inhibitors [3, 9] . Targeted therapies directed against single oncogene or single signaling pathway have produced major clinical responses in a fairly predictable manner [31] . However, these responses are often incomplete or not durable [32] . Multi-targeted therapies that simultaneously target several key oncogenes or signaling pathways are needed [33] . SC-535 assessed in this investigation is a novel small molecule multi-kinase inhibitor. Kinases V600E , BRAF WT , CRAF, KIT, and WT , and CRAF are key components of the MAPK signaling pathway, which is involved in various cellular functions, including cell proliferation, differentiation, and migration [4, 7, 37] .
As indicated above, melanomas are highly vascular tumors. Although antiangiogenic agent sorafenib failed as monotherapy in metastasized melanoma, a recent clinical study sorafenib [38] [39] [40] . Compared with sorafenib, SC-535 showed a higher potency in inhibition of several key kinases associated with angiogenesis, for example, the IC 50 value of SC-535 against VEGFR2 is 12 nM, and that of sorafenib is 90 nM. In vivo, it also displayed a better anti-tumor activity in WM2664 and C32 xenograft mouse models compared with sorafenib.
Flow cytometric analysis showed that SC-535 induced G2/M phase arrest, instead of apoptosis (that is one of the action mechanisms of sorafenib) [41] , in melanoma cells. This had no effect on apoptosis-related proteins such as Caspase3 and 9, Bax, and AKT. On the other hand, the cell cycle protein Cdk1, which must be activated for cells to enter mitosis, was inhibited by SC-535 in a dose dependent pattern. The inhibition of Cdk1 might be, at least partly, due to the blockade of MAPK signaling and the down-regulation of Cdc25C by SC-535 [42, 43] .
Recently, several studies have reported that selective BRAF inhibitors might lead to drug resistance in most clinical cases because BRAF inhibition can re-activate MAPK signaling in melanoma cells via the ERK-dependent feedback [32, 44, 45] . They also demonstrated that elevated CRAF protein levels were responsible for the primary insensitivity to RAF inhibition [46, 47] . SC-535 inhibited both BRAF and CRAF, which might help to overcome the resistance to BRAF inhibition. This hypothesis is supported by the fact that we did not observe increased ERK activation in WM2664 cells after 24 h treatment of SC-535 in various concentrations.
In conclusion, we have assessed the preclinical anti-melanoma activities for the novel multi-kinase inhibitor SC-535. The results showed that this compound had a considerable potency in anti-melanoma both in vitro and in vivo. Mechanism studies have indicated that it has a strong antiangiogenesis activity. SC-535 can arrest the tumor cell cycle in G2/M phase, other than induce apoptosis. SC-535 has the convenience of oral administration, favorable pharmacokinetic properties and low toxicity. Collectively, this study establishes a favorable -dies as a single agent or combination with other targeted agents or chemotherapeutic drugs in patients with melanoma. 
